Covance: New offering applies Chiltern-developed engagement models

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Image Source)
(Image: Getty/Image Source)

Related tags: Pharmacology, Clinical trial

LabCorp’s Covance has launched a new dedicated offering for biotech, medical device, and diagnostic companies following its purchase of Chiltern in 2017.

These client segments have specific needs for their clinical trials, which can be different from those of larger biopharma companies​,” said Lewis Cameron, head of Global Clinical Development, Covance.

The offering applies “customized engagement models successfully developed by Chiltern​,” he told us.

Chiltern joined Covance, the drug development division of LabCorp, after being acquired in September 2017​ for $1.2bn.

The new dedicated offering, announced Monday, also provides access to additional resources provided by Covance and LabCorp, said Cameron, and includes access to the Covance MarketPlace, the company’s proprietary model for connecting biotech companies with co-development or investment partners.

Cameron explained the addition of Chiltern strengthened Covance’s “focus on the biotech client segment and deepened our therapeutic expertise, particularly in oncology​.”

“Chiltern also brought comprehensive capabilities in medical device development​,” he said, explaining that the company is “pleased​” with the progress of the Chiltern integration to date.

This offering demonstrates how we’re working to translate the powerful combination of Covance and Chiltern to benefit our clients​.”

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Related suppliers

Follow us

Products

View more